OBIO logo

Orchestra BioMed Holdings, Inc.

OBIO
Healthcare|Biotechnology|US
$5.68
+0.06 (+1.07%)
Tangible Book / Share
$0.46
Cash / Share
$1.72

About

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.

Stock Price

+49.1%(1Y)
1M
-0.9%
3M
+34.0%
6M
+40.6%
YTD
+36.9%
1Y
+50.3%
3Y
+12.7%
5Y
-42.5%

Pipeline Summary

2 total trials
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 2

Active Trials (2)

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension
N/ARecruiting
Enrollment: 316 participants
Virtue® SAB in the Treatment of Coronary ISR Trial
NCT07045194Coronary Artery Disease
N/ARecruiting
Enrollment: 740 participants

Key Facts

Market Cap$341.4M
Employees86 (+23% YoY)
CEODavid Hochman
IPO DateAug 4, 2020
Beta0.55
52-Week Range$3.46 – $6.5
Avg Volume321,321
ExchangeNASDAQ

Ownership

Float68.9%
Shares Outstanding60.1M

Recent Insider Trades

Sherman DarrenSELL
Nov 2, 202615,000 shares @ $5.74
Sherman DarrenSELL
Oct 1, 202615,000 shares @ $6.36
Hochman David PTAX W/H
Sep 10, 20263,283 shares @ $5.81
Hochman David PTAX W/H
Sep 10, 20263,283 shares @ $5.81
Hochman David PBUY
Sep 3, 202610,000 shares @ $4.79

Peers

AVTXAvalo Therapeutics, Inc.
$371.7M
CRBUCaribou Biosciences, Inc.
$48.1M
ENTAEnanta Pharmaceuticals, Inc.
$320.4M
EPRXEupraxia Pharmaceuticals Inc.
$455.2M
IVAInventiva S.A.
$197.5M
IVVDInvivyd, Inc.
$165.9M
PRLDPrelude Therapeutics Incorporated
$287.3M
PYXSPyxis Oncology, Inc.
$105.2M
Data last updated: Nov 9, 2026, 04:25 AM